RALEIGH, N.C. Salix Pharmaceuticals announced its agreement with Novel Labs to settle its patent litigation over Novel’s proposed generic version of MoviPrep. Pending approval by the court, Salix, ...
RALEIGH, N.C.--(BUSINESS WIRE)-- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that Salix and Norgine B. V. have entered into an agreement with Novel Laboratories, Inc. to settle patent ...
PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Detailed results from a Phase 2B study of the lead formulation of a novel colonoscopy prep (ECP) being developed by ColonaryConcepts, LLC show the ...
The low-volume bowel preparation MoviPrep provided a noninferior alternative to the standard high-volume GoLYTELY in a cohort of hospitalized patients undergoing colonoscopy, a randomized trial showed ...
PHILADELPHIA — Low-volume bowel preparation is noninferior in adequacy to standard-volume prep in hospitalized patients undergoing colonoscopy, according to a study presented at the American College ...
The product is the generic of Velinor AG’s MoviPrep (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution). It is a low ...
Nycomed and Norgine, a European specialty pharmaceutical company, announced that they have entered into a licensing agreement that gives Nycomed the exclusive rights to commercialise Moviprep, the ...
RICHMOND HILL, ON, Dec. 5 /PRNewswire/ - Norgine, the leading European specialty pharmaceutical company, has today announced that it has granted Medical Futures the exclusive rights to market MOVIPREP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results